Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | GCG | P01275 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 2/20 | 0.32 |
| ▸ | CTSA | P10619 | 2/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | EEF2K | O00418 | 1/20 | 0.30 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.30 |
| ▸ | GCGR | P47871 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20032347 | 0.94 | KCNH2 (0.36) | KCNH2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL18713808 | 0.91 | KCNH2 (0.44) | KCNH2GCGMETCTSACHRM3 | |
| SCHEMBL20032465 | 0.89 | KCNH2 (0.36) | KCNH2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL21366928 | 0.89 | KCNH2 (0.43) | KCNH2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20032373 | 0.88 | KCNH2 (0.38) | KCNH2CTSACHRM3DPP4 | |
| SCHEMBL18713559 | 0.85 | KCNH2 (0.42) | KCNH2GCGMETCTSACHRM3 | |
| SCHEMBL20032433 | 0.82 | PTGDR2 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL20032482 | 0.82 | TRPV1 (0.36) | KCNH2CTSAGCGR | |
| SCHEMBL21366762 | 0.81 | PSEN1 (0.39) | KCNH2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20032474 | 0.80 | AKR1C3 (0.36) | KCNH2PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | KCNH2 3159/4885PSEN1 2972/4885PSEN2 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.